Press Releases Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
5.66 ^USD	-0.35%		+8.64%	-1.74%

Jul. 11	Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors	CI
May. 13	Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors	Jul. 11	AQ
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	May. 15	AQ
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	May. 13	AQ
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	May. 07	AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	May. 01	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	Apr. 25	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	Mar. 21	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	Mar. 18	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	Mar. 15	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	Mar. 13	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	Mar. 11	AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	Jan. 05	AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million	Jan. 02	AQ
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea	Dec. 06	AQ
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	Nov. 07	AQ
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023	23-10-31	AQ
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 vs. Solodyn	23-10-23	AQ
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)	23-10-20	AQ
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations	23-09-06	AQ
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	23-08-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Journey Medical Corporation

Equities

DERM

US48115J1097

Press Releases

Filters